PreComb Therapeutics
Private Company
Total funding raised: $2.8M
Overview
PreComb Therapeutics is a private, pre-revenue company based in Basel, Switzerland, offering a high-throughput, automated functional profiling platform for oncology. Its 3DTwin® system screens patient-derived tumor models against various therapies to predict drug response dynamics, supporting critical development decisions like candidate prioritization and combination design. The company positions itself as a translational research partner, aiming to reduce downstream clinical trial failure risk by providing more clinically predictive data earlier in the drug development process.
Technology Platform
3DTwin® Dynamic Drug Response Screening: A high-throughput, automated platform using patient-derived 3D microtumors for longitudinal functional profiling of drug response, adaptation, and resistance dynamics.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
PreComb competes in the translational oncology tools market against providers of patient-derived organoid (PDO) services, patient-derived xenograft (PDX) models, and other functional diagnostic platforms. Differentiation is claimed through longitudinal, high-throughput, automated profiling of dynamic response and resistance.